India, one of the world's fastest-growing major economies, is projected to experience a slowdown in 2025. Several factors ...

The freeze has put orders and forecasts, particularly those made months in advance, on hold. Read more at straitstimes.com.

The U.S. foreign aid freeze has severely impacted the supply chain for medical products in poor countries, causing potential shortages in HIV and malaria treatments. This disruption affects major ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

In fiscal 2024, the exports to the U.S. were worth $8.7 billion, or about 31% of total pharma exports, per data from government-backed trade body Pharmexcil. Trump's threat to raise tariffs sent ...

U.S. President Donald Trump's proposed tariffs on semiconductors and pharmaceutical imports threaten India's generics industry, a major supplier to the U.S. market. With 31% of their exports sent to ...

HYDERABAD, India (Reuters) - Indian pharmaceutical companies will be able to retain their dominant market share in the U.S.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Mumbai: Cipla, an Indian multinational pharmaceutical company, has announced that the United States Food and Drugs ...

Mumbai: Pharma major, Cipla, has received final approval from the United States Food and Drug Administration (USFDA) for the New Drug Application (‘NDA’) submitted for ‘Nilotinib Capsules 50, ...

IST, the barometer index, the S&P BSE Sensex, declined 461.33 points or 0.61% to 75,274.63. The Nifty 50 index slipped 139.85 points or 0.63% to 22,768.05.

The domestic benchmark indices were trading nearly flat in the morning trade on Friday amid mixed global cues, as automobile ...